Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY: CVM )

0.3014 +0.0142 (+4.94%)
Streaming Delayed Price Updated: 10:29 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 393,912
Open 0.2928
Bid (Size) 0.3012 (3)
Ask (Size) 0.3015 (8)
Prev. Close 0.2872
Today's Range 0.2900 - 0.3098
52wk Range 0.1800 - 2.390
Shares Outstanding 77,211,541
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
From CEL-SCI Corporation
Via Business Wire
Which stocks are moving on Monday?
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill

Performance

YTD
-27.36%
-27.36%
1 Month
+13.18%
+13.18%
3 Month
-25.89%
-25.89%
6 Month
-67.07%
-67.07%
1 Year
-79.50%
-79.50%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CEL-SCI Announces Pricing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
From CEL-SCI Corporation
Via Business Wire
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
From CEL-SCI Corporation
Via Business Wire
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of $5 Million Offering
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
Via Benzinga
Crude Oil Gains 1%; Chicago PMI Falls In December
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Lower; Dow Tumbles 600 Points
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Cel-Sci Shares Premarket On Monday?
Via Benzinga
US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking
Via Benzinga
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.